Mylan: Perbedaan antara revisi

Konten dihapus Konten ditambahkan
Penambahan referensi dari en.wp
k Perbaikan terjemahan, berdasar en.wp
Baris 68:
*Mylan Pharmaceuticals [[Unlimited liability corporation|ULC]], asal Etobicoke, Ontario<ref>{{Cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=6470453|title=Mylan Pharmaceuticals ULC: Private Company Information - Bloomberg|website=www.bloomberg.com|access-date=2018-06-11}}</ref>
*Mylan LLC, asal Caguas, Puerto Riko
*Mylan Technologies Inc. (MTI) - [[sistem pemberian obat transdermal]] (TDDS) dan teknologi terkait asal St. Albans, Vermont<ref>{{Cite news|url=https://www.biospace.com/article/releases/mylan-technologies-inc-expands-adds-160-new-jobs-/|title=Mylan Technologies Inc. Expands, Adds 160 New Jobs {{!}} BioSpace|work=BioSpace|access-date=2018-06-11|language=en-US}}</ref>
*UDL Laboratories Inc. asal Rockford, Illinois
*Somerset Pharmaceuticals Inc. sebuah perusahaan [[riset dan pengembangan]] asal [[Tampa, Florida]].<ref>{{Cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=34541|title=Somerset Pharmaceuticals, Inc.: Private Company Information - Bloomberg|website=www.bloomberg.com|access-date=2018-06-11}}</ref> Somerset mengembangkan [[Emsam]], yang diproduksi oleh Mylan Technologies dan dipasarkan di Amerika Serikat oleh Dey, yang kemudian diubah namanya menjadi Mylan Specialty<ref>{{cite web|url=http://www.dey.com/|title=Brand Name Medicines - Mylan|work=dey.com}}</ref><ref>{{cite web|url=http://www.mylan.com/global_reach/other_areas.aspx|title=About Us|work=mylan.com}}</ref><ref>{{Cite web|url=https://www.bizjournals.com/pittsburgh/news/2012/02/15/dey-pharma-to-change-to-mylan-specialty.html|title=Dey Pharma to Change to Mylan|website=www.bizjournals.com|access-date=2018-06-11}}</ref>
Baris 109:
 
===1980-an===
Dengan mulai berlakunya [[Undang-Undang Kompetisi Harga Obat dan Restorasi Syarat Paten|Undang-Undang Hatch-Waxman]] pada tahun 1984, Mylan dan produsen generik kecil lain mendapat keuntungan. Delapan belas bulan setelah undang-undang tersebut diberlakukan, pendapatan Mylan tumbuh sebesar 166% darimenjadi $12,5 juta dan nilai sahamnya naik sebesar 800%.<ref>{{cite journal|last1=Lewis|first1=Ralph A.|title=The Emerging Effects of the Drug Price Competition and Patent Term Restoration Act of 1984|journal=Journal of Contemporary Health Law & Policy|date=1992|volume=8|issue=1|pages=361–378|url=http://scholarship.law.edu/cgi/viewcontent.cgi?article=1539&context=jchlp}}</ref>
 
==Referensi==